Lifespan extension therapy: D-Glucosamine may increase life span via up-regulation of its target gene BubR1, 13/February/2018, 12.04 am

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture encompassing  Pyridoxamine and Pantoprazole   increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 12/February/2018, 11.49 pm
February 12, 2018
Combinatorial therapy for Myocardial Infarction:  A pharmaceutical mixture encompassing Pyridoxamine (PM) (Vitamine-B6) and Omeprazole (LP) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 13/February/2018, 12.15 am
February 12, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Lifespan extension therapy: D-Glucosamine may increase life span via up-regulation of its target gene BubR1


What is known? 

D-Glucosamine has been shown to extend lifespan. However, the exact mechanism of action is far from clear.


From Research Findings to Therapeutic Opportunity: 

Figure 1. A therapeutic mix encompassing D-Glucosamine  may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. The chemical structure of D-Glucosamine .

This study suggests, for the first time, that D-Glucosamineby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

 

 

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing D-Glucosamine  or its analogues, either alone or in combination with other drugs may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How D-Glucosamine  increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy: D-Glucosamine may increase life span via up-regulation of its target gene BubR1, 13/February/2018, 12.04 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.